MD-76R (Diatrizoate Meglumine / Diatrizoate Sodium) - Drug Interactions, Contraindications, Overdosage

DRUG INTERACTIONS

Drug/Laboratory Test Interactions: Iodine-containing contrast agents may alter the results of thyroid function tests which depend on iodine estimation, e.g., PBI and radioactive iodine uptake studies. Such tests, if indicated, should be performed prior to the administration of this preparation or delayed for about two weeks following administration.

Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards.

Following selective coronary arteriography, transient elevation of creatinine phosphokinase (CPK) has occurred in approximately 30% of patients tested.

Post-arteriographic changes in laboratory studies include transient elevations in BUN, serum creatinine and glucose.

Hypertonic solutions cause a decrease in hematocrit in vitro and in vivo, and shrinkage of red blood cells.

OVERDOSAGE

Overdosage may occur. The adverse effects of overdosage are life-threatening and affect mainly the pulmonary and cardiovascular system. The symptoms may include cyanosis, bradycardia, acidosis, pulmonary hemorrhage, convulsions, coma and cardiac arrest. Treatment of an overdose is directed toward the support of all vital functions and prompt institution of symptomatic therapy.

Diatrizoate salts are dialyzable.

The intravenous LD₅₀ value of diatrizoate meglumine and diatrizoate sodium (in grams of iodine/kilogram body weight) varied from 5.3 to 6.1 g/kg in mice. The LD₅₀ values decrease as the rate of injection increases.

CONTRAINDICATIONS

MD-76R should not be used for myelography.

Refer to PRECAUTIONS, General concerning hypersensitivity.